Article Details
Retrieved on: 2022-02-14 20:21:41
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Gilead Sciences Inc (NASDAQ: GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in ...
Article found on: www.benzinga.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here